NERV — Minerva Neurosciences, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1598646 ·
Last close
$2.16
Market Cap
$103.13M
52W High
$8.80
52W Low
$1.96
ADV30
178,899
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -9,433,677 100,746,561 98,278,196 20,216,241 195,802,092
Jun 2026 0 — -10,642,159 17,466,285 95,088,945 24,652,086 308,389,568
Mar 2026 0 — -16,671,552 -125,404,384 94,027,156 32,659,770 348,041,016
Dec 2025 0 — -4,981,589 -283,667,663 97,968,888 82,301,813 238,716,970

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-26,168,723
Investing CF
$-50,127,329
Financing CF
$85,700,228
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-28.87
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-796,737,839
Inventory
—
Receivables
—
ST Investments
$50,615,164
EBIT TTM
$-313,725,328
Pretax Income TTM
$-394,349,716
Interest Exp TTM
$0
Analysts
3

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -15,102,970 -293,423,177 97,968,888 238,716,970 -140,748,082 -13,510,936
Dec 2024 0 -21,848,386 1,438,865 37,143,744 62,836,844 -25,693,100 -19,550,567
Dec 2023 0 -23,119,576 -30,005,353 56,899,750 85,357,240 -28,457,490 -14,784,732
Dec 2022 0 -25,231,326 -32,108,676 55,087,233 75,111,452 -20,024,219 -24,645,143

TTM Snapshot

Revenues TTM
$1,852,356
NetIncome TTM
$-394,349,716
OpCashFlow TTM
—
Assets (Latest)
$95,088,945
Forward EPS
$-0.42

Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $2.50 · spot: $2.18 · call volume: 3 · put volume: 0
Expected Move to 2026-12-18: ±$1.40 (64.22%) — implied range $0.78 – $3.58 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
CATX Perspective Therapeutics, Inc. $103.84M $0.86 —
OGI ORGANIGRAM GLOBAL INC. $101.90M $0.71 —
OKUR OnKure Therapeutics, Inc. $104.50M $2.58 —
UNCY Unicycive Therapeutics, Inc. $101.35M $3.70 —
ORGO Organogenesis Holdings Inc. $105.35M $0.81 —

News headlines (Yahoo Finance, 1h cache)

Minerva Neurosciences: Q3 Earnings Snapshot
2026-11-06 14:08 · Yahoo
Minerva Neurosciences Provides Third Quarter 2026 Financial Results and Business Updates
2026-11-06 14:00 · Yahoo
Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London
2026-10-29 11:00 · Yahoo
Minerva Neurosciences to Host In-Person KOL Event to Discuss Roluperidone for Negative Symptoms of Schizophrenia
2026-10-28 11:00 · Yahoo
Minerva Neurosciences to Participate in Two Upcoming Investor Conferences
2026-08-28 12:00 · Yahoo
Minerva Announces Leadership Transition
2026-04-02 20:05 · Yahoo
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
2026-06-01 20:05 · Yahoo
All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy
2026-05-20 16:00 · Yahoo
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
2026-03-31 20:05 · Yahoo
Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
2026-05-05 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.